Forbes June 5, 2024
Arianna Johnson

Topline

A Food and Drug Administration expert panel voted Wednesday to manufacture new COVID-19 vaccines to specifically target the JN.1 variant lineage—which makes up the most dominant strains circulating in the U.S.

Key Facts

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.

When Will Each Covid Vaccine Be Ready?

Each drugmaker gave different timelines for when their supplies will be ready. Bill Falstich, Pfizer’s vice president of global supply chain, primary care, said during the meeting his company’s vaccine will be ready immediately upon approval, and the company has “evaluated the expected demand… and we expect that...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article